Although the aforementioned compounds have been found to be effective in limiting tau phosphorylation for applications in AD treatment, limitations such as low bioaccumulation, insignificant in vivo circulation times, and non‐specific targeting abilities have restricted the effectiveness of these therapeutic compounds. Here, MAPT is linked to Alzheimer disease.